To characterize gastrointestinal adverse events (AEs) with different glucagon-like peptide-1 receptor agonists (GLP-1RAs).
| INTRODUCTION
In patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonists (GLP-1RAs) lead to significant reductions in glycated haemoglobin (HbA1c) levels and body weight, and are now approved and used across the spectrum of T2D therapies, as an adjunct to diet and exercise, oral agents or insulin. 1 GLP-1RAs are associated with gastrointestinal adverse events (AEs), predominantly nausea, vomiting and diarrhoea. They act by stimulating insulin release and suppressing glucagon secretion in a glucose-dependent fashion, while increasing satiety, slowing gastric emptying and inhibiting small intestinal motility. 2, 3 Differences between individual GLP-1RAs have been observed regarding the type and frequency of gastrointestinal events, 1 which may be related to the specific agent and/or to pharmacokinetic differences. It is now understood that with short-acting GLP-1RAs, such as exenatide twice daily and lixisenatide, postprandial glucose reduction is associated with substantial slowing of gastric emptying, whereas the slowing of gastric emptying is much less pronounced with longer-acting GLP-1RAs, such as liraglutide and exenatide once weekly. 4, 5 Similar incidence rates for nausea, vomiting and diarrhoea have been reported among patients receiving exenatide twice daily and liraglutide once daily, although nausea was less persistent with liraglutide compared with exenatide twice daily, 6 whereas lower incidences have been reported with exenatide once weekly. 4, 7, 8 More information is needed, however, on the specific gastrointestinal 
| MATERIALS AND METHODS
This was a post hoc analysis of individual patient data from studies in the exenatide once-weekly development programme, with 6-month safety data in which exenatide once weekly was compared directly with another GLP-1RA. Two analyses of patient-level data were performed: a pooled analysis of three studies comparing exenatide once weekly with exenatide twice daily (DURATION-1, DURATION-5 and NCT00917267), 4, 7, 9 and a separate analysis of the DURATION-6 study, which compared exenatide once weekly and liraglutide. 8 The designs, inclusion and exclusion criteria, and primary findings of these studies have been reported elsewhere. 4, [7] [8] [9] All studies were randomized, multicentre, open-label trials designed to evaluate glycaemic control over treatment periods ranging from 24 to 30 weeks (Table S1 , Supporting Information). 4, [7] [8] [9] Typical titration schedules were followed for exenatide twice daily and liraglutide, with no titration required for exenatide once weekly (Table S1 , Supporting Information). Final doses of study medication were exenatide once weekly 2 mg, exenatide twice daily 10 μg and liraglutide once daily 1.8 mg.
| Recording of gastrointestinal AEs
The data comprised spontaneous, patient-reported gastrointestinal AEs recorded at study visits. The nature and severity of AEs described by patients were recorded by the investigator and were not adjudicated or assessed for severity according to any systematic rating scale. Gastrointestinal AEs were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) terms.
Because investigators were not instructed as to how to define gastrointestinal AE terms, terms other than nausea, vomiting and diarrhoea were included. A list of all reported gastrointestinal AE terms, which did not specify treatment assignment, was reviewed by a gastroenterologist (C.K.R.). Oral events and those with known causes (eg, structural or infectious disorders) were excluded (Table S2 , Supporting Information).
Gastrointestinal AEs of interest ( 
| Event timing
The timing of specific gastrointestinal AEs was studied with reference to treatment initiation (days on therapy) when an individual event was studied. The proportion of patients with an AE was calculated using the number of patients remaining in the study at each time interval as the denominator. When the timing of multiple gastrointestinal AEs was studied, one was defined as the reference event and the timing of other events was calculated as days before or after the first occurrence of this event.
| Statistical analyses
All analyses were conducted for the intention-to-treat populations of the included studies, defined as all randomized patients who had taken ≥1 dose of study drug. Only gastrointestinal AEs with onset or worsening after the first randomized study medication dose were analysed. For the purpose of integration, all AEs were re-coded using Subgroups with <30 patients were considered to be of insufficient size for statistical analysis.
| RESULTS

| Study population
The pooled analysis population included 1223 patients (exenatide once weekly, n = 617; exenatide twice daily, n = 606) and the DURATION-6 analysis included 911 patients (exenatide once weekly, n = 461; liraglutide, n = 450).
Patient characteristics in the two populations were generally similar; however, the pooled analysis included a greater proportion of Asian patients (56% vs 12%) and a smaller proportion of white patients (31% vs 65%) than DURATION-6, and patients in the pooled analysis had numerically lower mean body weight and body mass index (Table 1) .
| Incidences of gastrointestinal AEs
Overall, gastrointestinal AEs of interest occurred in a smaller proportion of patients treated with exenatide once weekly vs exenatide twice daily (34% vs 45%; P < .0001), and with exenatide once weekly vs liraglutide (25% vs 41%; P < .0001; Figure 1A and B).
Fewer upper gastrointestinal AEs were noted for exenatide once weekly compared with exenatide twice daily and liraglutide, respectively ( Figure 1A and B); this applied to patients reporting only upper gastrointestinal AEs with exenatide once weekly vs exenatide twice daily (P < .0001), exenatide once weekly vs liraglutide (P < .001), and to those reporting both upper and lower gastrointestinal AEs with exenatide once weekly vs liraglutide (P < .001). There were no between-group differences in the proportion of patients with only lower gastrointestinal AEs in either analysis.
Analysis of lower gastrointestinal AEs by type (diarrhoea, constipation or both) showed no difference between exenatide once weekly and exenatide twice daily, although fewer patients treated with exenatide once weekly vs liraglutide reported lower gastrointestinal AEs (P < .01; Table 2 ). The only significant between-group difference for individual lower gastrointestinal AEs was that fewer patients reported diarrhoea with exenatide once weekly than with liraglutide (P < .001).
"Pancreatitis" or "acute pancreatitis" was recorded for one patient each in both the pooled analysis and DURATION-6; these patients were in the exenatide once-weekly group. Individual Abbreviations: BMI, body mass index; FPG, fasting plasma glucose.
1 Studies included DURATION-1, DURATION-5 and NCT00917267.
2 Use of metformin alone or in combination with sulphonylurea, thiazolidinedione, insulin, or other glucose-lowering therapy.
gastrointestinal AEs reported in each treatment group are presented in Table S4 , Supporting Information.
| Patient subgroups 3.3.1 | Sex
A greater proportion of women than men reported gastrointestinal AEs in both the pooled analysis (P < .05 for exenatide once weekly; P < .0001 for exenatide twice daily) and DURATION-6 (P < .01 for exenatide once weekly; P < .01 for liraglutide; Table 2 ).
| Race/ethnicity
There were differences in the proportion of patients reporting gastrointestinal AEs when categorized by race/ethnicity in both analyses, but the direction of the difference was inconclusive ( Table 2 ). In the pooled analysis, the proportion of patients with gastrointestinal AEs in the exenatide once-weekly group was lower for Asian and Hispanic patients than for white patients (both P < .001), without any difference for exenatide twice-daily-treated patients. In DURATION-6, the proportion of patients with gastrointestinal AEs was higher for Asian than for white patients with both exenatide once weekly (P < .05) and liraglutide (P < .01), with no differences between Hispanic and white patients.
| Background metformin use
Continued use of metformin was not associated with increased gastrointestinal AEs in the pooled population (Table 2) .
| Timing of gastrointestinal AEs
Nausea was the most common gastrointestinal AE throughout the treatment period but differed between the GLP-1RAs. For exenatide once weekly, few patients reported nausea during each 2-week interval, and the proportion was consistently lower than with exenatide twice daily or liraglutide ( Figure 1C and D) . With exenatide twice daily, nausea incidence peaked at weeks 4 to 6 and declined thereafter; for liraglutide, the proportion of patients reporting nausea was highest during the first 4 weeks, before decreasing.
The proportions of patients reporting vomiting, diarrhoea and constipation during any 2-week interval were <7%, <9% and <5%, respectively, for all treatments.
Vomiting remained infrequent throughout treatment with exenatide once weekly in the pooled analysis, while there was a peak at weeks 4 to 6 for exenatide twice daily. Similarly in DURATION-6, vomiting remained uncommon for exenatide once weekly throughout, but peaked during weeks 0 to 4 for liraglutide.
Diarrhoea was more frequent with exenatide once weekly (peaking at weeks 2-4) than with exenatide twice daily (peaking at weeks 
| Severity, serious events and events leading to withdrawal
Gastrointestinal AEs were predominantly mild (74.8% for exenatide once weekly and 75.5% for exenatide twice daily; 83.0% for exenatide once weekly and 74.3% for liraglutide).
In the pooled analysis, mild, moderate and severe gastrointestinal 
Discontinuation because of gastrointestinal AEs was infrequent
and occurred less with exenatide once weekly vs exenatide twice daily (1% vs 6% of patients; P < .0001) and exenatide once weekly vs liraglutide (1% vs 4% of patients; P < .05). Nausea and vomiting were the gastrointestinal AEs that most often led to withdrawal of exenatide twice daily and liraglutide; no trend was apparent for exenatide once weekly (Table S6 , Supporting Information). In the exenatide twice-daily and liraglutide groups, nausea events that led to withdrawal mainly occurred within the first month of treatment.
| Association between gastrointestinal AEs and treatment effects
Reductions from baseline in HbA1c and body weight occurred with all treatments at week 26 (all P < .05 vs baseline). The reduction in HbA1c did not differ between patients with upper and/or lower gastrointestinal AEs and those without in any analysis ( Figure 2E ).
Weight loss was greater in patients who reported gastrointestinal
AEs than in those who did not in the exenatide once-weekly (−2.7 kg vs −2.0 kg; P < .05) and exenatide twice-daily groups (−2.8 kg vs −2.0 kg; P < .05) in the pooled analysis ( Figure 2F ). There were no differences in weight loss for exenatide once weekly or liraglutide in DURATION-6 ( Figure 2F ).
| DISCUSSION
Gastrointestinal symptoms occur frequently in patients with T2D and represent a substantial cause of morbidity, 10 so it is important to understand the potential effects of medications on these symptoms.
GLP-1RAs have been shown to reduce HbA1c and body weight, with low intrinsic risk of hypoglycaemia. One potential AE associated with these agents is an increase in gastrointestinal events that is transient in most cases. 1 As such, understanding the specific gastrointestinal AE profile and how it varies across the GLP-1RA class is of interest for patients and physicians, and may be useful in guiding therapy.
Both pooled patient-level data and a single trial were studied in the present analysis, so that data for three separate GLP-1RAs were available. The most common gastrointestinal AEs reported were nausea, vomiting and diarrhoea. Other diagnoses, including dyspepsia and gastroesophageal reflux disease, were also associated with the GLP-1RAs studied, but differed between individual GLP-1RAs and were reported less frequently (Table S4 , Supporting Information). The results also suggest that some patients experience both upper and lower gastrointestinal AEs, most commonly nausea followed within 10 days by diarrhoea-an observation not, to our knowledge, previously reported.
Incidences of gastrointestinal AEs differed between the GLP1RAs investigated. Upper gastrointestinal AEs were less common for exenatide once weekly, compared with exenatide twice daily and 2 White subgroup used as reference for comparisons.
3 Metformin alone or in combination with other oral glucose-lowering drugs or insulin.
liraglutide. In contrast, the frequency of lower gastrointestinal AEs was similar across treatment groups, although diarrhoea occurred more frequently with liraglutide than with exenatide once weekly.
Constipation was uncommon, and most patients reporting constipation also reported diarrhoea at a different time during treatment.
While constipation has been reported by patients treated with GLP1RAs, its incidence in clinical trials has varied considerably between agents. [11] [12] [13] [14] [15] [16] Patients who reported both upper and lower gastrointestinal AEs were more commonly treated with liraglutide than with exenatide once weekly; however, there was no significant difference [27] [28] [29] ; it is possible that these differences impact centrally mediated AEs. It was recently established that tachyphylaxis occurs for the effects of exogenous glucagon-like peptide-1 on the slowing of gastric emptying with prolonged exposure. 30 Thus, while short-acting GLP-1RAs such as exenatide twice daily are likely to have a sustained effect to slow gastric emptying substantially, this effect is likely to be markedly diminished with longer-acting formulations such as exenatide once weekly or liraglutide. 4, 26 It is unknown whether a similar phenomenon applies to the effects of GLP-1RAs on other gut regions (eg, the small or large intestine), or for the central effects of these agents.
In the present analysis we also examined whether any patient characteristics influenced the gastrointestinal effects of GLP-1RAs.
For all treatments, upper gastrointestinal AEs were reported more frequently by women than men; this is consistent with pooled analyses of 7 studies of exenatide once weekly 31 and 16 studies involving exenatide twice daily. 32 Even aside from drug studies, gastrointestinal symptoms are consistently reported more frequently in women than men, with or without diabetes, 10 for reasons that are not well understood.
When analysed by race/ethnicity, there were inconsistent outcomes for comparisons of exenatide once weekly vs exenatide twice daily and exenatide once weekly vs liraglutide. This suggests that race/ethnicity has little, if any, effect on the occurrence of gastrointestinal AEs and is consistent with previous pooled analyses of 7 exenatide once-weekly studies 31 and 16 exenatide twice-daily studies. 32 Finally, metformin use had no significant effect on the proportion of patients experiencing gastrointestinal AEs. This contrasts with a previous study indicating a strong association of diarrhoea and faecal incontinence with metformin use in T2D. 33 Given that metformin use was stable before study entry, it is possible that individuals who had AEs from metformin were not represented in the study populations.
Limitations inherent in post hoc analyses include their retrospective nature and the potential for selection bias resulting from differences between patients eligible for clinical trials and those seen in clinical practice. Furthermore, we focused on three specific GLP-1RAs evaluated in the exenatide once-weekly development programme, rather than the class as a whole, and the studies were not placebo-controlled (ie, the lack of a placebo group made it difficult to determine how many gastrointestinal AEs were unrelated to study medication); moreover, patient histories of gastrointestinal disorders before study entry were not systematically recorded.
Recording of gastrointestinal AEs was based on patient reports, which are likely to represent an underestimate of the true incidences. 34 Furthermore, gastrointestinal AE data were not adjudi- 
